Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Bayer Making A Mistake With Monsanto When Pharma Is Its Leading Business?

Executive Summary

Second-quarter earnings results have raised questions about Bayer AG's long-term strategy, including over how long the company's pharma unit can continue to come out on top and drive the group based on the performance of just five "recently" marketed drugs.

Advertisement

Related Content

4Q Pharma Results Preview, Part 3: Gilead, GSK, Sanofi, Allergan, Shire, Bayer, Valeant
Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel